Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery Lesions

Journal of Endovascular Therapy

Volumn 24, Issue 6, 2017, Pages 783-792

  de Boer, Sanne W ^a   van den Heuvel, Daniel A F ^a   de Vries Werson, Debbie A B ^a   Vos, Jan Albert ^a   Fioole, Bram ^b   Vroegindeweij, Damnis ^b   Elgersma, Otto E ^c   Tutein Nolthenius, Rudolph P ^c   Heyligers, Jan M M ^d   Bosma, Gerlof P T ^d   de Leeuw, Bernart ^e   Bouwman, Lee H ^e   Böckler, Dittmar ^f   Dovzhanskiy, Dmitriy I ^f   Vos, Floris W F ^g   Vink, Ted W F ^g   Hooijboer, Pieter G A ^h   Hissink, Rutger J ^h   de Vries, Jean Paul P M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b Maasstad Hospital Rotterdam   (Netherlands)

^c ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^d CPRLab   (Netherlands)

^e Sittard Geleen Heerlen   (Netherlands)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g MEDICAL CENTER LEEUWARDEN   (Netherlands)

^h Scheper Ziekenhuis   (Netherlands)

Author keywords

balloon angioplasty; drug coated balloon; drug eluting balloon; multicenter trial; paclitaxel; peripheral artery disease; randomized trial; self expanding stent; superficial femoral artery

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; ALLOY; BIOCOMPATIBLE COATED MATERIAL; CARDIOVASCULAR AGENT; NITINOL; PACLITAXEL;

ADULT; AGED; ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ARTICLE; BARE METAL STENTING; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EVALUATION AND FOLLOW UP; FEMALE; FEMOROPOPLITEAL BYPASS; HUMAN; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; RISK FACTOR; SHORT COURSE THERAPY; SUPERFICIAL FEMORAL ARTERY; ULTRASOUND; CLINICAL TRIAL; COMPARATIVE STUDY; DEVICES; DIAGNOSTIC IMAGING; DUPLEX DOPPLER ULTRASONOGRAPHY; EQUIPMENT DESIGN; FEMORAL ARTERY; GERMANY; NETHERLANDS; PATHOPHYSIOLOGY; SELF EXPANDABLE METALLIC STENT; TIME FACTOR; TREATMENT OUTCOME; VASCULAR ACCESS DEVICE; VASCULAR PATENCY;

AGED; ALLOYS; ANGIOGRAPHY; ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; EQUIPMENT DESIGN; FEMALE; FEMORAL ARTERY; GERMANY; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; SELF EXPANDABLE METALLIC STENTS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR ACCESS DEVICES; VASCULAR PATENCY;

EID: 85033797595     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1177/1526602817725062     Document Type: Article

References (39)

1. Newman AB, Shemanski L, Manolio TA, Ankle-arm index as a predictor of cardiovascular disease and mortality in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 1999;19:538–545.
2. Balzer JO, Thalhammer A, Khan V, Angioplasty of the pelvic and femoral arteries in PAOD: results and review of the literature. Eur J Radiol. 2010;75:48–56.
3. Zeller T., Current state of endovascular treatment of femoro-popliteal artery disease. Vasc Med. 2007;12:223–234.
4. Norgren L, Hiatt WR, Dormandy JA, Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
5. Hirsch AT, Haskal ZJ, Hertzer NR, ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)—summary of recommendations. J Vasc Interv Radiol. 2006;17:1383–1397.
6. European Stroke Organisation (ESO), Tendera M, Aboyans V, ESC guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2851–2906.
7. Laird JR, Katzen BT, Scheinert D, Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1–9.
8. Schillinger M, Sabeti S, Loewe C, Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–1888.
9. Rocha-Singh KJ, Jaff MR, Crabtree TR, Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69:910–919.
10. Chalmers N, Walker PT, Belli AM, Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study. Cardiovasc Intervent Radiol. 2013;36:353–361.
11. Duda SH, Bosiers M, Lammer J, Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710.
12. Tepe G, Schnorr B, Albrecht T, Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102–108.
13. Werk M, Albrecht T, Meyer DR, Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–840.
14. Werk M, Langner S, Reinkensmeier B, Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–1365.
15. Scheinert D, Duda S, Zeller T, The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–19.
16. Rosenfield K, Jaff MR, White CJ, Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.
17. Dake MD, Ansel GM, Jaff MR, Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.
18. Jens S, Conijn AP, Koelemay MJ, Randomized trials for endovascular treatment of infrainguinal arterial disease: systematic review and meta-analysis (Part 1: above the knee). Eur J Vasc Endovasc Surg. 2014;47:524–535.
19. Laird JR, Schneider PA, Tepe G, Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–2338.
20. Tepe G, Zeller T, Albrecht T, Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–699.
21. Bishu K, Armstrong EJ., Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence. Vasc Health Risk Manag. 2015;11:387–395.
22. Karimi A, de Boer SW, van den Heuvel DAF, Randomized trial of Legflow® paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol for a randomized controlled trial. Trials. 2013;14:87.
23. Schillinger M, Sabeti S, Dick P, Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–2749.
24. Liistro F, Grotti S, Porto I, Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (Drug Eluting Balloon in Peripheral Intervention for the Superficial Femoral Artery). JACC Cardiovasc Interv. 2013;6:1295–1302.
25. Brescia AA, Wickers BM, Correa JC, Stenting of femoropopliteal lesions using interwoven nitinol stents. J Vasc Surg. 2015;61:1472–1478.
26. Chan YC, Cheng SW, Ting AC, Primary stenting of femoropopliteal atherosclerotic lesions using new helical interwoven nitinol stents. J Vasc Surg. 2014;59:384–391.
27. Garcia L, Jaff MR, Metzger C, Wire-interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries: twelve-month results of the SUPERB trial. Circ Cardiovasc Interv. 2015;8(5). doi:10.1161/CIRCINTERVENTIONS.113.000937.
28. George JC, Rosen ES, Nachtigall J, SUPERA interwoven nitinol Stent Outcomes in Above-Knee IntErventions (SAKE) study. J Vasc Interv Radiol. 2014;25:954–961.
29. Scheinert D, Grummt L, Piorkowski M, A novel self-expanding interwoven nitinol stent for complex femoropopliteal lesions: 24-month results of the SUPERA SFA registry. J Endovasc Ther. 2011;18:745–752.
30. Werner M, Paetzold A, Banning-Eichenseer U, Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention. 2014;10:861–868.
31. Müller-Hülsbeck S, Keirse K, Zeller T, Twelve-month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther. 2016;23:701–707.
32. Dick P, Wallner H, Sabeti S, Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009;74:1090–1095.
33. Bosiers M, Deloose K, Callaert J, Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54:1042–1050.
34. Scheinert D, Scheinert S, Sax J, Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312–315.
35. Lin Y, Tang X, Fu W, Stent fractures after superficial femoral artery stenting: risk factors and impact on patency. J Endovasc Ther. 2015;22:319–326.
36. Myint M, Schouten O, Bourke V, A real-world experience with the Supera interwoven nitinol stent in femoropopliteal arteries: midterm patency results and failure analysis. J Endovasc Ther. 2016;23:433–441.
37. Bosiers M, Peeters P, Tessarek J, ; Zilver PTX Single-Arm Study Investigators. The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino). 2013;54:115–122.
38. Rychlik IJ, Davey P, Murphy J, A meta-analysis to compare Dacron versus polytetrafluoroethylene grafts for above-knee femoropopliteal artery bypass. J Vasc Surg. 2014;60:506–515.
39. Lumsden AB, Morrissey NJ, ; Comparison of Safety and Primary Patency Between the FUSION BIOLINE Heparin-Coated Vascular Graft and EXXCEL Soft ePTFE (FINEST) Trial Co-investigators. Randomized controlled trial comparing the safety and efficacy between the FUSION BIOLINE heparin-coated vascular graft and the standard expanded polytetrafluoroethylene graft for femoropopliteal bypass. J Vasc Surg. 2015;61:703–712.e1.